199 related articles for article (PubMed ID: 33437383)
21. SNHG5 enhances Paclitaxel sensitivity of ovarian cancer cells through sponging miR-23a.
Lin H; Shen L; Lin Q; Dong C; Maswela B; Illahi GS; Wu X
Biomed Pharmacother; 2020 Mar; 123():109711. PubMed ID: 31884343
[TBL] [Abstract][Full Text] [Related]
22. The Tubulin Inhibitor VERU-111 in Combination With Vemurafenib Provides an Effective Treatment of Vemurafenib-Resistant A375 Melanoma.
Cui H; Wang Q; Miller DD; Li W
Front Pharmacol; 2021; 12():637098. PubMed ID: 33841154
[TBL] [Abstract][Full Text] [Related]
23. Asparagus officinalis combined with paclitaxel exhibited synergistic anti-tumor activity in paclitaxel-sensitive and -resistant ovarian cancer cells.
Zhang X; Wang J; Fan Y; Zhao Z; Paraghamian SE; Hawkins GM; Buckingham L; O'Donnell J; Hao T; Suo H; Yin Y; Sun W; Kong W; Sun D; Zhao L; Zhou C; Bae-Jump VL
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3871-3883. PubMed ID: 36006482
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of ZEB1 leads to inversion of metastatic characteristics and restoration of paclitaxel sensitivity of chronic chemoresistant ovarian carcinoma cells.
Sakata J; Utsumi F; Suzuki S; Niimi K; Yamamoto E; Shibata K; Senga T; Kikkawa F; Kajiyama H
Oncotarget; 2017 Nov; 8(59):99482-99494. PubMed ID: 29245917
[TBL] [Abstract][Full Text] [Related]
25. Potent inhibition of tubulin polymerisation and proliferation of paclitaxel-resistant 1A9PTX22 human ovarian cancer cells by albendazole.
Chu SW; Badar S; Morris DL; Pourgholami MH
Anticancer Res; 2009 Oct; 29(10):3791-6. PubMed ID: 19846910
[TBL] [Abstract][Full Text] [Related]
26. Mechanisms of paclitaxel-induced apoptosis in an ovarian cancer cell line and its paclitaxel-resistant clone.
Sugimura M; Sagae S; Ishioka S; Nishioka Y; Tsukada K; Kudo R
Oncology; 2004; 66(1):53-61. PubMed ID: 15031599
[TBL] [Abstract][Full Text] [Related]
27. P21-activated kinase 1 regulates resistance to BRAF inhibition in human cancer cells.
Babagana M; Johnson S; Slabodkin H; Bshara W; Morrison C; Kandel ES
Mol Carcinog; 2017 May; 56(5):1515-1525. PubMed ID: 28052407
[TBL] [Abstract][Full Text] [Related]
28. Inhibiting BRAF Oncogene-Mediated Radioresistance Effectively Radiosensitizes BRAF
Robb R; Yang L; Shen C; Wolfe AR; Webb A; Zhang X; Vedaie M; Saji M; Jhiang S; Ringel MD; Williams TM
Clin Cancer Res; 2019 Aug; 25(15):4749-4760. PubMed ID: 31097454
[TBL] [Abstract][Full Text] [Related]
29. Downregulation of miRNA-31 induces taxane resistance in ovarian cancer cells through increase of receptor tyrosine kinase MET.
Mitamura T; Watari H; Wang L; Kanno H; Hassan MK; Miyazaki M; Katoh Y; Kimura T; Tanino M; Nishihara H; Tanaka S; Sakuragi N
Oncogenesis; 2013 Mar; 2(3):e40. PubMed ID: 23552883
[TBL] [Abstract][Full Text] [Related]
30. Tectorigenin sensitizes paclitaxel-resistant human ovarian cancer cells through downregulation of the Akt and NFκB pathway.
Yang YI; Lee KT; Park HJ; Kim TJ; Choi YS; Shih IeM; Choi JH
Carcinogenesis; 2012 Dec; 33(12):2488-98. PubMed ID: 23027625
[TBL] [Abstract][Full Text] [Related]
31. KDM5A promotes proliferation and EMT in ovarian cancer and closely correlates with PTX resistance.
Feng T; Wang Y; Lang Y; Zhang Y
Mol Med Rep; 2017 Sep; 16(3):3573-3580. PubMed ID: 28714030
[TBL] [Abstract][Full Text] [Related]
32. Side population is increased in paclitaxel-resistant ovarian cancer cell lines regardless of resistance to cisplatin.
Kobayashi Y; Seino K; Hosonuma S; Ohara T; Itamochi H; Isonishi S; Kita T; Wada H; Kojo S; Kiguchi K
Gynecol Oncol; 2011 May; 121(2):390-4. PubMed ID: 21272926
[TBL] [Abstract][Full Text] [Related]
33. p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells.
Park SH; Seong MA; Lee HY
Oncotarget; 2016 Feb; 7(7):8184-99. PubMed ID: 26799187
[TBL] [Abstract][Full Text] [Related]
34. Synergistic effect of piperine and paclitaxel on cell fate via cyt-c, Bax/Bcl-2-caspase-3 pathway in ovarian adenocarcinomas SKOV-3 cells.
Pal MK; Jaiswar SP; Srivastav AK; Goyal S; Dwivedi A; Verma A; Singh J; Pathak AK; Sankhwar PL; Ray RS
Eur J Pharmacol; 2016 Nov; 791():751-762. PubMed ID: 27756602
[TBL] [Abstract][Full Text] [Related]
35. Induction of a multifactorial resistance phenotype by high paclitaxel selective pressure in a human ovarian carcinoma cell line.
Violini S; D'Ascenzo S; Bagnoli M ; Millimaggi D; Miotti S; Canevari S; Pavan A; Dolo V
J Exp Clin Cancer Res; 2004 Mar; 23(1):83-91. PubMed ID: 15149155
[TBL] [Abstract][Full Text] [Related]
36. VCAM-1 Upregulation Contributes to Insensitivity of Vemurafenib in BRAF-Mutant Thyroid Cancer.
Chen S; Su X; Jiang X; Zhang T; Min I; Ding Y; Wang X; Mao Z; Cao J; Teng X; Fahey TJ; Wang W; Teng L
Transl Oncol; 2020 Feb; 13(2):441-451. PubMed ID: 31911278
[TBL] [Abstract][Full Text] [Related]
37. Curcuma zedoaria (Berg.) Rosc. essential oil and paclitaxel synergistically enhance the apoptosis of SKOV3 cells.
Zhou Y; Shen J; Xia L; Wang Y
Mol Med Rep; 2015 Jul; 12(1):1253-7. PubMed ID: 25777341
[TBL] [Abstract][Full Text] [Related]
38. BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression.
Kim SH; Ryu H; Ock CY; Suh KJ; Lee JY; Kim JW; Lee JO; Kim JW; Kim YJ; Lee KW; Bang SM; Kim JH; Lee JS; Ahn JB; Kim KJ; Rha SY
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30326563
[TBL] [Abstract][Full Text] [Related]
39. JD enhances the anti-tumour effects of low-dose paclitaxel on gastric cancer MKN45 cells both in vitro and in vivo.
Wang C; Wang R; Zhou K; Wang S; Wang J; Shi H; Dou Y; Yang D; Chang L; Shi X; Liu Y; Xu X; Zhang X; Ke Y; Liu H
Cancer Chemother Pharmacol; 2016 Nov; 78(5):971-982. PubMed ID: 27620208
[TBL] [Abstract][Full Text] [Related]
40. Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts.
Ricci F; Guffanti F; Damia G; Broggini M
Mol Cancer; 2017 May; 16(1):97. PubMed ID: 28558767
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
